Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Return on Equity: 2010-2025

Historic Return on Equity for Madrigal Pharmaceuticals (MDGL) over the last 11 years, with Sep 2025 value amounting to -0.43%.

  • Madrigal Pharmaceuticals' Return on Equity rose 20.00% to -0.43% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.43%, marking a year-over-year increase of 20.00%. This contributed to the annual value of -0.80% for FY2024, which is 44.00% up from last year.
  • Madrigal Pharmaceuticals' Return on Equity amounted to -0.43% in Q3 2025, which was down 7.99% from -0.40% recorded in Q2 2025.
  • Madrigal Pharmaceuticals' Return on Equity's 5-year high stood at -0.40% during Q2 2025, with a 5-year trough of -5.82% in Q3 2022.
  • Its 3-year average for Return on Equity is -1.42%, with a median of -0.63% in 2024.
  • Its Return on Equity has fluctuated over the past 5 years, first slumped by 488bps in 2022, then skyrocketed by 489bps in 2024.
  • Quarterly analysis of 5 years shows Madrigal Pharmaceuticals' Return on Equity stood at -1.12% in 2021, then crashed by 172bps to -2.84% in 2022, then surged by 109bps to -1.75% in 2023, then surged by 114bps to -0.61% in 2024, then rose by 20bps to -0.43% in 2025.
  • Its Return on Equity stands at -0.43% for Q3 2025, versus -0.40% for Q2 2025 and -0.53% for Q1 2025.